In conclusion, they established that 400 mg biweekly Vorinostat paired with 250 mg daily Gefitinib is the optimal dose for phase II investigations in patients with NSCLC who are positive for both BIM deletion polymorphisms and EGFR mutations [105]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.